Use of and spending on supportive care medications among Medicare beneficiaries with cancer
- 268 Downloads
The study objective was to provide population-based estimates of supportive care medication (SCM) use among Medicare beneficiaries with cancer and determine factors related to SCM receipt.
This retrospective cohort study of community-based Medicare beneficiaries used the Medicare Current Beneficiary Survey (1997–2007). Dependent variables comprised use and spending on SCMs for three medication classes: opioids, antidepressants/sedative/hypnotics (ASH), and antiemetics. Independent variables of interest were supplemental insurance coverage, cancer site, and treatment. Multivariate models determined factors affecting receipt of, and spending on, SCMs. We also compared SCM use and spending among beneficiaries with and without cancer in order to understand what portion of SCM use and spending could be attributed to cancer as opposed to other comorbid conditions.
A total of 1,836 Medicare beneficiaries with cancer and 9,898 beneficiaries without cancer were eligible for the study. Beneficiaries with cancer were more likely to receive opioids, ASH, and antiemetics compared to non-cancer beneficiaries. Adjusted annual payments for antiemetics were on average $637 higher in with cancer versus without cancer (p < 0.01), while ASH payments were $184 lower (p < 0.01). Opioid spending was similar among cancer and non-cancer users. Relative to colon cancer, beneficiaries with prostate cancer were least likely to receive any of the three SCM classes. Receipt of antineoplastic treatment increased the probability of use of all three classes of SCMs. Insurance coverage did not influence the use of or spending on opioids or antiemetics, but was associated with both outcomes for ASH. The use of all three SCM classes was significantly lower during years before Part D implementation of the new Medicare Part D prescription drug benefit and was higher after implementation of Part D.
This study provides population-based information on SCM use among Medicare beneficiaries with cancer. Cancer site and treatment modality were important predictors of SCM use.
KeywordsCancer Medicare Part D Supportive care
Funding sources American Cancer Society RSGI-10-109-01-CPHPS and Supplemental Medical and Drug Insurance and Cancer Related Spending are gratefully acknowledged by the authors.
This article was initiated while Dr. Davidoff was employed at the University of Maryland Baltimore. The opinions expressed in this article are the author’s own and do not reflect the view of the Agency for Healthcare Research and Quality, the Department of Health and Human Services, or the US government.
Portions of this paper were presented at Harry and Elsa Jiler—American Cancer Society Professors Meeting, November 1, 2011.
Conflict of interest
None of the authors have a personal financial relationship with the organization that sponsored the research. The sponsor (American Cancer Society) had no role in the design, methods, data collection, analysis, or preparation of the paper.
- 2.Christensen S, Shinogle J (1997) Effects of supplemental coverage on use of services by Medicare enrollees. Health Care Financing Rev 19(1):5Google Scholar
- 3.Cipriano LE, Romanus D, Earle CC, Neville BA, Halpern EF, Gazelle GS, McMahon PM (2011) Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health 14(1):41–52. doi: 10.1016/j.jval.2010.10.006 PubMedCentralPubMedCrossRefGoogle Scholar
- 4.Davidoff AJ, Rapp T, Onukwugha E, Zuckerman IH, Hanna N, Pandya N, Mullins CD (2009) Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation. Med Care 47(12):1229–1236Google Scholar
- 9.Kaa K (2007) Medicare challenges and solutions—reimbursement issues in treating the patient with colorectal cancer. J Manag Care Pharm JMCP 13(6 Suppl C):S19–26Google Scholar
- 12.Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Piantedosi FV, Cigolari S, Illiano A, Barbera S, Robbiati SF, Piazza E, Ianniello GP, Frontini L, Veltri E, Castiglione F, Rosetti F, De Maio E, Maione P, Gridelli C, Rossi A, Barletta E, Barzelloni ML, Signoriello G, Bilancia D, Dinota A, Rosati G, Germano D, Lamberti A, Pontillo V, Brancacio L, Crispino C, Esposito M, Battiloro C, Tufano G, Cioffi A, Guardasole V, Angelini V, Guidetti G, Renda F, Romano F, Volpintesta A, Sannicolo M, Filipazzi V, Esani G, Gambaro A, Ferrario S, Tinessa V, Caprio MG, Zonato S, Cabiddu M, Raina A, D’Aprile M, Pistillucci G, Porcile G, Ostellino O, Vinante O, Azzarello G, Gebbia V, Borsellino N, Testa A, Gasparini G, Morabito A, Gattuso D, Romito S, Carrozza F, Fava S, Calcagno A, Grimi E, Bertetto O, Ciuffreda L, Parello G, Maiorino L, Santoro A, Santoro M, Failla G, Aiello RA, Bearz A, Sorio R, Scalone S, Clerici M, Bollina R, Belloni P, Sacco C, Sibau A, Adamo V, Altavilla G, Scimone A, Spatafora M, Bellia V, Hopps MR, Monfardini S, Favaretto A, Stefani M, Corradini GM, Pavia G, Scagliotti G, Novello S, Selvaggi G, Tonato M, Darwish S, Michetti G, Belometti MO, Labianca R, Quadri A, De Marinis F, Migliorino MR, Martelli O, Colucci G, Galetta D, Giotta F, Isa L, Candido P, Rossi N, Calandriello A, Ferrau F, Malaponte E, Barni S, Cazzaniga M, Gebbia N, Valerio MR, Belli M, Colantuoni G, Capuano MA, Angiolillo M, Sollitto F, Ardizzoia A, Luporini G, Locatelli MC, Pari F, Aitini E, Pedicini T, Febbraro A, Zollo C, Di Costanzo F, Bartolucci R, Gasperoni S, Gaion F, Palazzolo G, Galligioni E, Caffo O, Cortesi E, D’Auria G, Curcio C, Vasta M, Bumma C, Celano A, Bretti S, Nettis G, Anselmo A, Mattioli R, Nistico C, Aschelter A, Foa P (2003) Supportive care in patients with advanced non-small-cell lung cancer. British J Cancer 89(6):1013–10.1038/sj.bjc.6601236CrossRefGoogle Scholar
- 13.Christensen S, Zachariae R, Jensen AB, Vaeth M, Moller S, Ravnsbaek J, von der Maase H (2009) Prevalence and risk of depressive symptoms 3–4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. Breast Cancer Res Treat 113(2):339–355. doi: 10.1007/s10549-008-9920-9 PubMedCrossRefGoogle Scholar
- 15.Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19(1):131–140. doi: 10.1007/s00520-009-0797-x PubMedCrossRefGoogle Scholar
- 23.Suppli NP, Deltour I, Damkjaer LH, Christensen J, Jensen AB, Kroman NT, Johansen C, Dalton SO (2011) Factors associated with the prescription of antidepressive medication to breast cancer patients. Acta Oncologica (Stockholm, Sweden) 50(2):243–251. doi: 10.3109/0284186x.2010.531049 CrossRefGoogle Scholar
- 24.Carr D, Goudas L, Lawrence D, Pirl W, Lau J, DeVine D, Kupelnick B, Miller K (2002) Management of cancer symptoms: pain, depression, and fatigue. AHRQ Evidence Report/Technology Assessment (Summary) (61) (61):1-5Google Scholar
- 28.Medicare Current Beneficiary Survey (MCBS). (2012) Centers for Medicare & Medicaid Services. http://www.cms.gov/Research-Statistics-Data-and-Systems/Research/MCBS/index.html?redirect=/MCBS/. (Accessed 21 Jan 2013)Google Scholar
- 30.NCCN (2012) Distress management version 3.2012. NCCN, Fort WashingtonGoogle Scholar